# Question 3

**Type:** Basic/statistical

**Question:** What clinical attributes are there in the MSK CHORD study?

**Answer:**

Perfect! Now I have a comprehensive view of the clinical attributes available in the MSK CHORD study. Here's a summary of the clinical attributes:

## Clinical Attributes in MSK CHORD Study

### Sample-level Clinical Attributes (25,040 samples):
- **CANCER_TYPE** - General cancer type classification
- **CANCER_TYPE_DETAILED** - Detailed cancer type classification
- **CLINICAL_GROUP** - Clinical grouping (20,376 samples)
- **CLINICAL_SUMMARY** - Clinical summary information (24,552 samples)
- **DIAGNOSIS_DESCRIPTION** - Detailed diagnosis description
- **FRACTION_GENOME_ALTERED** - Genomic instability measure (24,870 samples)
- **GENE_PANEL** - Gene panel used for sequencing
- **GLEASON_SAMPLE_LEVEL** - Gleason score at sample level (2,110 samples)
- **ICD_O_HISTOLOGY_DESCRIPTION** - ICD-O histology classification
- **METASTATIC_SITE** - Site of metastasis (8,834 samples)
- **MSI_COMMENT** - Microsatellite instability comments (19,343 samples)
- **MSI_SCORE** - Microsatellite instability score (24,487 samples)
- **MSI_TYPE** - Microsatellite instability type (24,486 samples)
- **MUTATION_COUNT** - Total number of mutations (23,862 samples)
- **ONCOTREE_CODE** - OncoTree cancer type code
- **PATHOLOGICAL_GROUP** - Pathological classification (17,767 samples)
- **PDL1_POSITIVE** - PD-L1 status (3,526 samples)
- **PRIMARY_SITE** - Primary tumor site
- **SAMPLE_CLASS** - Sample classification
- **SAMPLE_COVERAGE** - Sequencing coverage information
- **SAMPLE_TYPE** - Type of sample (e.g., primary, metastatic)
- **SOMATIC_STATUS** - Somatic mutation status
- **TMB_NONSYNONYMOUS** - Tumor mutational burden (non-synonymous)
- **TUMOR_PURITY** - Estimated tumor purity (24,454 samples)

### Patient-level Clinical Attributes (24,950 patients):
- **ADRENAL_GLANDS** - Adrenal gland involvement
- **BONE** - Bone involvement
- **CNS_BRAIN** - Central nervous system/brain involvement
- **CURRENT_AGE_DEID** - De-identified current age (24,947 patients)
- **ETHNICITY** - Patient ethnicity
- **GENDER** - Patient gender
- **GLEASON_FIRST_REPORTED** - First reported Gleason score (3,250 patients)
- **GLEASON_HIGHEST_REPORTED** - Highest reported Gleason score (3,250 patients)
- **HER2** - HER2 status (5,368 patients)
- **HISTORY_OF_PDL1** - History of PD-L1 treatment (6,992 patients)
- **HR** - Hormone receptor status (5,368 patients)
- **INTRA_ABDOMINAL** - Intra-abdominal involvement
- **LIVER** - Liver involvement
- **LUNG** - Lung involvement
- **LYMPH_NODES** - Lymph node involvement
- **NUM_ICDO_DX** - Number of ICD-O diagnoses
- **OS_MONTHS** - Overall survival in months
- **OS_STATUS** - Overall survival status
- **OTHER** - Other sites of involvement
- **PLEURA** - Pleural involvement
- **PRIOR_MED_TO_MSK** - Prior medical history before MSK
- **RACE** - Patient race
- **REPRODUCTIVE_ORGANS** - Reproductive organ involvement
- **SAMPLE_COUNT** - Number of samples per patient
- **SMOKING_PREDICTIONS_3_CLASSES** - Smoking status prediction
- **STAGE_HIGHEST_RECORDED** - Highest recorded disease stage

The MSK CHORD study appears to be a comprehensive dataset with rich clinical annotations covering demographics, tumor characteristics, treatment history, metastatic sites, and genomic features across thousands of cancer patients and samples.

---

*Generated on 2025-07-14 18:07:12*
